# POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.

> **NCT07433192** · — · RECRUITING · sponsor: **Servier Russia** · enrollment: 300 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07433192
- **Lead sponsor:** Servier Russia
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07433192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07433192, "POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07433192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*